(1) TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and efficacy profile Biogen's expansion in China now includes treatment options approved for relapsing MS and spinal muscular atrophy CAMBRIDGE, Mass., April 15, 2021(Nasdaq: BIIB) today announced that China's National Medical Products Administration (NMPA) has approved TECFIDERA (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS). First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience.